Remove Blogging Remove Develop Remove Sales Remove Thousand Oaks
article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

The deal also includes a $175 million deferred payment due in 2019 and $850 million in downstream payouts tied to regulatory and sales targets. —South San Francisco, CA-based Denali Therapeutics, with ambitions to develop drugs for several neurodegenerative diseases, bagged $130 million in a Series B and unveiled a series of deals.

Pricing 40
article thumbnail

Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More

Xconomy

Then came the rumor mill: Companies may or may not be approaching Biogen about a sale, and Biogen may or may not be fielding offers. Instead, Holmes promoted a new system, MiniLab , in development. Holmes claimed it would be able to produce multiple test results from a single blood sample without shipping blood to a lab.

News 40